Annual Report: 2024
Veeda Clinical Research Limited 20th Annual Report F.Y. 2023-2024 summary:
Veeda Clinical Research Limited will hold its Twentieth Annual General Meeting (AGM) on Friday, December 13th, 2024, at 1100 hours at its Corporate Office in Ahmedabad, Gujarat. The agenda includes the following business:
Ordinary Business:
Special Business:
Regarding remuneration increases for Mr. Nitin Deshmukh and Mr. Rakesh Bhartia, the Nomination and Remuneration Committee recommended an increase of INR 10 lakh per year for each director, resulting in a total remuneration of INR 2.08 lakh per month for each. The Board subsequently approved this recommendation on October 25th, 2024. The Board recommends the approval of the resolutions related to these increases.
Notes regarding the AGM: The Board of Directors had approved the application for an extension of timeline for holding an Annual General Meeting of the Company, The Registrar of Companies, Gujarat approved the request and considered the extension of 1 month and 0 days for holding of an Annual General Meeting. A member entitled to attend and vote can appoint a proxy, who need not be a member. Proxies must be deposited at the registered office 48 hours before the meeting. Corporate members sending representatives must provide certified Board Resolutions/Power of Attorney. All documents are available for inspection at the registered office.
Directors' Report: Veeda Clinical Research Limited:
Financial Highlights: The company presents its 20th Annual Report, including audited financial statements for the year ended March 31, 2024. The following is a summary of financial performance:
| PARTICULARS | STANDALONE (INR in millions) | CONSOLIDATED (INR in millions) | | --------------------------------------- | ----------------------------- | ----------------------------- | | | 2023-24 | 2022-23 | 2023-24 | 2022-23 | | Revenue of Operations | 2,754.48 | 2,961.53 | 3,887.77 | 4,095.78 | | Other Income | 175.61 | 91.47 | 192.13 | 106.32 | | Profit before Interest, Depreciation, Amortization & Tax | 455.20 | 635.62 | 714.51 | 1140.54 | | Interest and Financial charges | 58.73 | (53.32) | 148.35 | (138.82) | | Depreciation | 350.21 | (211.32) | 533.57 | (380.25) | | Share of profit / (loss) from joint venture and associate (net of tax) | - | - | - | (26.67) | | Exceptional Items | - | - | - | - | | Profit/(Loss) before taxes | 46.26 | 370.98 | 32.59 | 594.80 | | Current Tax | 37.71 | (126.14) | (97.98) | (192.79) | | Adjustment of tax relating to earlier years | (9.69) | (0.12) | 8.19 | 2.93 | | Deferred Tax | (12.34) | 14.80 | 53.62 | 19.29 | | Profit / (Loss) for the Year | 30.58 | 259.52 | (3.58) | 424.23 |
Business Performance:
Dividend: The directors do not recommend a dividend on equity shares for the year ended March 31st, 2024, to conserve resources for future growth. Transfer to Reserves: The directors do not recommend any amount to be transferred to any reserve. Major Events during the Year:
As of the report date, the company owns 91.00% of shareholding of M/s. Bioneeds India Private Limited. The company has invested in equity shares and Compulsory Convertible Preference Shares of Veeda Clinical Research Ireland Limited (a wholly owned subsidiary).
The company aims to list the company's equity shares on one or more recognized stock exchanges. There are no material orders passed by regulators, courts, or tribunals impacting the company's operation.
The authorized share capital is Rs. 36,44,06,800, comprising of 18,22,03,400 Equity Shares of Rs.2 each. During the year, 1,01,05,860 equity shares were allotted. 100% of the Company's paid-up Equity Share Capital is in dematerialized form as on March 31st, 2024. The Company has adequate internal control systems.
Key aspects of the internal control system include adherence to accounting standards/policies, preparation of budgets, and asset safeguards. The company also uses an external audit firm as an internal auditor. There were no outstanding deposits as defined by the Act.
During the financial year, the company provided a loan to the Ingenuity Biosciences Private Limited. There was Investment through acquisition of 196 Ordinary Shares and 98 C Ordinary Shares of in Health Data Specialists by subsidiary company
There were also investments made Equity Shares of Veeda Clinical Research Ireland in Bioneeds India and Health Data Specialists.
The company has altered the Articles of Association. Directors affirm that applicable accounting standards have been followed, policies are consistently applied, proper care is taken for accounting records, and the annual accounts are prepared on a going concern basis with adequate internal controls.
The company received declarations from independent directors meeting independence criteria.
The Board is satisfied with the integrity, expertise, and experience of the independent directors. A Nomination and Remuneration Policy is in place. The company has a robust Risk Management Policy. A Whistle Blower Policy is in place.
All contracts/arrangements with related parties were at arm's length.
The Company has a Corporate Social Responsibility (CSR) Committee and policy. The Chief Financial Officer certified that CSR spends were utilized as approved.
The company has not taken any loans from banks or financial institutions and hence the difference in valuation is not applicable.
Veeda continues to focus on attracting, hiring, training, and inducting top industry talent.
The Company consistently enables employees to be empowered, happy, and enthusiastic about their work. The total rewards program emphasizes equality.
M/s. SRBC & Co. LLP were appointed as Statutory Auditors. Their report does not contain any qualification, reservation, or adverse remark, except with respect to CARO. M/s. Pradip R. Shah & Co. was appointed as Internal Auditor. M/s. Tushar Vora & Associates was appointed as Secretarial Auditor. The Secretarial Audit Report has no qualification, reservation, or adverse remark. Provisions of Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014 are not applicable.
The Annual Return is available on the company's website.
The company has complied with all applicable provisions of Secretarial Standard-1 and Secretarial Standard-2. The Company's facilities are adequately insured. Information is provided on conservation of energy, technology absorption, and foreign exchange earnings/outgo in Annexure-F.
The Company is committed to a workplace free of Sexual Harassment, and a redressal mechanism for complaints is in place. Details are provided on Corporate Identity Number and details of top 10 employees' remuneration. Information is provided on Auditors, Share Capital and related details, and Internal Control Systems and their Adequacy. Veeda's vision statement embodies a focus on increasing its relevance to its clients and being their preferred partners. Veeda intends to increase presence across regulated markets in the US and the EU and increase the focus on pre-clinical services.
Access essential information and documents to make informed investment decisions
Stay updated with upcoming events, conferences, and announcements
Access quarterly and half-yearly financial statements and reports
Download comprehensive annual reports and financial summaries
Access investor presentations, corporate briefings, and slideshows
Our blog provides insightful information about unlisted shares, offering a deeper understanding of how these assets work, their potential benefits, and the risks involved. Whether you're new to unlisted shares or looking to expand your knowledge, we cover topics such as investment strategies, valuation methods, market trends, and regulatory aspects. Stay updated with expert tips and guides to navigate the unlisted share market effectively.
Unlisted shares are stocks of companies that are not listed on any stock exchange, meaning they are not publicly traded. These shares are typically available for trade in the private market through brokers, and can offer unique investment opportunities.
You can buy unlisted shares through a broker or platform that specializes in unlisted share transactions. We provide a secure and easy way to purchase unlisted shares from top companies, ensuring a smooth transaction process.
The share prices of unlisted companies can fluctuate based on various factors like market demand, company performance, and private transactions. You can check the latest share prices for unlisted companies on our website for real-time updates.
Unlisted shares can offer higher growth potential, as they are typically not subject to the same market volatility as listed shares. However, they come with higher risk due to limited liquidity and availability of information. It's important to research thoroughly and consult experts before investing.
To sell unlisted shares, you can connect with a broker or platform that facilitates the sale of private stocks. We help investors buy and sell unlisted shares with ease, ensuring that your transaction is handled professionally and securely.
Yes, unlisted shares can eventually be listed on a stock exchange through an Initial Public Offering (IPO). This process allows the company to offer its shares publicly and be traded on major exchanges, potentially increasing liquidity and visibility.
Gains from unlisted shares are subject to capital gains tax in India. Short-term capital gains (if held for less than 24 months) are taxed at your applicable income tax rate, while long-term capital gains (if held for more than 24 months) are taxed at 20% with indexation benefits. Always consult a tax advisor for precise tax implications.
The value of unlisted shares is typically determined by private transactions, financial reports, and market demand. We provide the latest updates on share prices of unlisted companies, giving you the most accurate valuation available.
The minimum investment for unlisted shares can vary depending on the company and broker. Generally, the minimum investment is higher than for listed stocks, but we provide detailed information to help you make the best investment decisions.
Yes, unlisted shares may pay dividends if the company has declared them. However, since these companies may be in their growth stage, dividend payments are not always guaranteed. It's important to check the company's financial health before investing.
It's important to conduct thorough research on the company's financials, management, market potential, and overall business model. You can also seek professional advice from experts to help you choose unlisted shares with strong growth prospects.
Gains from unlisted shares are subject to capital gains tax in India. Short-term capital gains (if held for less than 24 months) are taxed at your applicable income tax rate, while long-term capital gains (if held for more than 24 months) are taxed at 20% with indexation benefits. Always consult a tax advisor for precise tax implications.
